Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-6036 + bevacizumab
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
GDC-6036 + bevacizumab is an experimental combination therapy being evaluated for the treatment of advanced or metastatic solid tumors with KRAS G12C mutations. GDC-6036 (also known as divarasib) is a highly selective, irreversible inhibitor of KRAS G12C, designed to lock the mutant KRAS protein in an inactive state and suppress its oncogenic signaling. Bevacizumab is an approved monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing tumor angiogenesis. The combination aims to both directly inhibit cancer cell growth (via KRAS G12C inhibition) and deprive tumors of blood supply (via VEGF inhibition)[1][3][4][5][6].
02
Targets
HRAS (H-Ras protein)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)NRAS G12CVEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on GDC-6036 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDC-6036 + bevacizumab.